These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8996137)

  • 1. Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.
    Robins HI; Rushing D; Kutz M; Tutsch KD; Tiggelaar CL; Paul D; Spriggs D; Kraemer C; Gillis W; Feierabend C; Arzoomanian RZ; Longo W; Alberti D; d'Oleire F; Qu RP; Wilding G; Stewart JA
    J Clin Oncol; 1997 Jan; 15(1):158-64. PubMed ID: 8996137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia.
    Robins HI; Katschinski DM; Longo W; Grosen E; Wilding G; Gillis W; Kraemer C; Tiggelaar CL; Rushing D; Stewart JA; Spriggs D; Love R; Arzoomanian RZ; Feierabend C; Alberti D; Morgan K; Simon K; d'Oleire F
    Cancer Chemother Pharmacol; 1999; 43(5):409-14. PubMed ID: 10100597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.
    Robins HI; Cohen JD; Schmitt CL; Tutsch KD; Feierabend C; Arzoomanian RZ; Alberti D; d'Oleire F; Longo W; Heiss C
    J Clin Oncol; 1993 Sep; 11(9):1787-94. PubMed ID: 8355046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease.
    Robins HI; D'Oleire F; Grosen E; Spriggs D
    Anticancer Res; 1997; 17(4B):2891-4. PubMed ID: 9329556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole body hyperthermia induction of soluble tumor necrosis factor receptors: implications for rheumatoid diseases.
    Robins HI; Grosen E; Katschinski DM; Longo W; Tiggelaar CL; Kutz M; Winawer J; Graziano F
    J Rheumatol; 1999 Dec; 26(12):2513-6. PubMed ID: 10606355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma.
    Page RL; Thrall DE; Dewhirst MW; Macy DW; George SL; McEntee MC; Heidner GL; Novotney CA; Allen SA; Withrow SJ
    Int J Hyperthermia; 1991; 7(4):559-66. PubMed ID: 1919151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma.
    Wiedemann GJ; d'Oleire F; Knop E; Eleftheriadis S; Bucsky P; Feddersen S; Klouche M; Geisler J; Mentzel M; Schmucker P
    Cancer Res; 1994 Oct; 54(20):5346-50. PubMed ID: 7923163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
    J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia.
    Robins HI; d'Oleire F; Kutz M; Bird A; Schmitt-Tiggelaar CL; Cohen JD; Spriggs DR
    Cancer Lett; 1995 Feb; 89(1):55-62. PubMed ID: 7882302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
    Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
    Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations.
    Robins HI; Longo WL; Steeves RA; Cohen JD; Schmitt CL; Neville AJ; O'Keefe S; Lagoni R; Riggs C
    Int J Radiat Oncol Biol Phys; 1990 Apr; 18(4):909-20. PubMed ID: 2182581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
    Bakhshandeh A; Bruns I; Eberhardt K; Wiedemann GJ
    Dtsch Med Wochenschr; 2000 Mar; 125(11):317-9. PubMed ID: 10761473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor.
    Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer.
    Robins HI; Sielaff KM; Storer B; Hawkins MJ; Borden EC
    Cancer Res; 1989 Mar; 49(6):1609-15. PubMed ID: 2647291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
    Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
    Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.